agree this needs changed with the extra clarifies you have…UTD has some controversy here on whether low dose ASA even does anything (limited data it seems) but mentions many patients reasonably still take it…UpToDate
I also suggest we clarify primary vs secondary thrombosis prevention. Primary thrombosis prevention = antithrombotic therapy used in patients with obstetric antiphospholipid syndrome (APS) or isolated antiphospholipid antibodies (aPL) without APS-related thrombosis. Secondary thrombosis prevention = period after the initial 3-6 months of treatment for the acute thrombotic event. (according to UTD)
didnt know that! thank you alex, i definitely think we should add that somewhere, especially the primary and secondary thrombosis prevention, just hated how vague this card was, even if we left it as anticoagulants but talked more about it in the extra that’s fine too
I think we should change this card to test on the first line thromboprophylaxis regimen for APS. I will make that change and you all approve if you agree
can you clarify what you mean by “first line thromboprophylaxis regimen for APS”? Do you mean primary or secondary prophylaxis based on the UTD/amboss definitions above? I just want the note to be very clear in the text bc as it’s currently written “first-line prophylactic treatment for antiphospholipid syndrome” does not clarify primary vs secondary imo.
edited extras as Secondary thromboprophylaxis was incorrectly given " (meaning no active or recent thrombus when treatment is initiated) approach is low-dose aspirin (controversy to this)"
Wouldnt first line be low dose aspirin if its primary thromboprophylaxis? Unless we state that the card is asking for secondary thromboprophylaxis, or we can even include primary and secondary but dont know if that is asked for in step 1